Cancer Research UK Policy – A new report showing how cancer strategies can drive improvements in outcomes
Mark Lawler shared a post by Cancer Research UK Policy, on X:
“Delighted to see Cancer Research UK Policy quoting our data on cancer policy consistency to underpin their new report calling for a cancer plan. As I said in to the House of Commons Select Committee Future Cancer Inquiry, the decision to abandon a national cancer plan was utter madness.”
Quoting Cancer Research UK Policy‘s post:
“Today we have published a new report showing how cancer strategies can drive improvements in outcomes.
We’re calling on the incoming UK Government to commit to a long-term plan for England and make this election a Turning Point for Cancer.”
Read further.
Source: Mark Lawler/X and Cancer Research UK Policy/X
Professor Mark Lawler holds the positions of Associate Pro-Vice-Chancellor, Professor of Digital Health, and Chair in Translational Cancer Genomics at the Faculty of Medicine, Health and Life Sciences at Queen’s University Belfast (QUB).
He serves on the Board of the European Alliance for Personalised Medicine (EAPM) and was instrumental in developing EAPM’s research strategy. Additionally, he is a member of the Scientific Advisory Board of the European Cancer Patient Coalition and the Strategic Advisory Board of Genomics England. His expertise includes genetics, precision medicine, health data, COVID-19, cancer, and patient and public involvement in research.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023